Skip to main content
BIOXYNE LIMITED logo

BIOXYNE LIMITED — Investor Relations & Filings

Ticker · BXN ISIN · AU000000BXN6 LEI · 984500F02D2B1B94E956 ASX Manufacturing
Open in API
Filings indexed 842 across all filing types
Latest filing 2025-06-17 Capital/Financing Update
Country AU Australia
Listing ASX BXN

About BIOXYNE LIMITED

https://bioxyne.com

Bioxyne Limited is a life sciences company focused on the development, manufacture, and commercialization of health and wellness products. The company specializes in proprietary probiotic strains, notably the Lactobacillus fermentum VRI-003 (PCC), which is utilized in supplements targeting immune health and gut function. Following the acquisition of Breathe Life Sciences, Bioxyne has expanded its portfolio into the medicinal cannabis sector, novel foods, and consumer health products. Its operations encompass the production and distribution of pharmaceutical-grade cannabis products, CBD-based wellness items, and functional supplements. The company serves international markets through a vertically integrated model, focusing on research-driven formulations and high-quality manufacturing standards to address growing consumer demand for therapeutic and preventative health solutions.

Recent filings

Filing Released Lang Actions
Enters German Market Euro3.2m Manufacturing & Supply Agmt 3 pages 332.4KB
Capital/Financing Update Classification · 95% confidence The document is a press release dated 18 June 2025 announcing Bioxyne Limited's entry into the German medical cannabis market through a manufacturing and supply agreement valued at approximately A$5.6 million for FY2026. It details the commercial agreement, key highlights, company background, and market outlook. There are no financial statements, quarterly or annual results, nor any regulatory filings or certifications. The content focuses on a business update regarding a new contract and market expansion, which fits the category of Capital/Financing Update (CAP) as it relates to a significant commercial agreement expected to generate revenue. The document length is about 5987 characters, sufficient for a detailed announcement but not a full financial report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-06-17 English
Webinar Update - Reset to 19 June 2025 3 pages 93.2KB
Investor Presentation Classification · 80% confidence The document is a short announcement dated 18 June 2025 from Bioxyne Limited regarding a reset of a business update webinar originally planned for 18 June 2025 and rescheduled to 19 June 2025. It includes details about the webinar, key discussion points such as FY2025 revenue guidance, market progress updates, and a positive outlook for FY2026. The document does not contain any financial statements, detailed financial data, or comprehensive analysis. It is primarily an announcement about an event (webinar) and its rescheduling, not a report or transcript. The length is 4713 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a call transcript, earnings release, or annual/interim report. The document also does not fit into categories like management changes, legal proceedings, or capital updates. Given these factors, the most appropriate classification is Investor Presentation (IP) because the webinar is a presentation focused on business updates and financial guidance, or alternatively Regulatory Filings (RNS) if considered a general announcement. However, since it is specifically about a business update webinar with key discussion points and outlook, Investor Presentation (IP) is the best fit with moderate confidence.
2025-06-17 English
FY25 Revenue Guidance Upgrade 3 pages 182.8KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement dated 12 June 2025 from Bioxyne Limited (ASX:BXN) upgrading its full year FY2025 revenue guidance from $25 million to $28 million. It provides key highlights of revenue growth, market updates, and outlook for FY2026. The text is focused on revenue guidance and business progress rather than presenting full financial statements or detailed financial analysis. It is not a full annual report or interim report, nor is it a transcript, audit report, or other regulatory filing. The document is a capital/financing update as it relates to revenue guidance and business outlook, which fits the Capital/Financing Update (CAP) category. The document length (5625 characters) and content support this classification with high confidence.
2025-06-11 English
Bioxyne to Host Webinar 18 June 2025 at 5PM AEST 2 pages 182.3KB
Investor Presentation Classification · 90% confidence The document is a business update announcement for FY2025 by Bioxyne Limited, inviting investors to a webinar where the Managing Director will discuss revenue guidance, market progress, and developments. It includes no detailed financial statements or comprehensive financial analysis, but rather a forward-looking business update and invitation to an event. The document length is 4103 characters, which is relatively short and more consistent with an announcement or presentation invitation rather than a full report. There is no indication that this is a full Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a regulatory filing or certification. The content aligns best with an Investor Presentation (IP) or a business update presentation. Given the webinar format and focus on business update and guidance, the classification as Investor Presentation (IP) is most appropriate with high confidence.
2025-06-11 English
Invitation to Investor Webinar 1 May 2025 at 4PM AEST 3 pages 264.0KB
Investor Presentation Classification · 90% confidence The document is an announcement inviting shareholders and prospective investors to an online investor webinar hosted by Bioxyne Limited. It includes details about the event, such as date, time, presenter, and registration link. The content focuses on providing an update on the company and engaging in a live Q&A session. There are no financial statements, detailed financial analysis, or comprehensive report data included. The document is relatively short (4637 characters) and serves as an invitation and informational notice about the webinar event rather than a full investor presentation or financial report. Therefore, the most appropriate classification is 'Investor Presentation' (IP), as the webinar is a presentation aimed at investors focusing on company updates and engagement.
2025-04-29 English
Quarterly Activities/Appendix 4C Cash Flow Report 11 pages 551.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Q3 ACTIVITIES REPORT 31 MARCH 2025' and contains detailed financial and operational information for the quarter ending March 31, 2025. It includes revenue figures, cash receipts, cash flow statements, capital expenditures, operational updates, and outlook commentary. The presence of an Appendix 4C quarterly cash flow report, which is a regulatory requirement for Australian listed companies, further confirms this is a quarterly financial report. The document is approximately 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The content focuses on quarterly financial performance and operational activities rather than annual results or full-year financial statements, which aligns with an Interim / Quarterly Report. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). Q3 2025
2025-04-27 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.